Zacks Investment Research on MSN4h
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...
Zacks Investment Research on MSN22h
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Multiple Sclerosis News Today1d
Tysabri may reduce risk of disability progression in SPMS: Analysis
A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...
7 Stocks Still Trading Below COVID Lows 5 Years Later
Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.
MedPage Today1d
Deciding Whether Multiple Sclerosis Treatment Should Be Discontinued
Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...
Multiple Sclerosis News Today4d
First-line Tysabri better at reducing MS relapse rates, healthcare use
Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...